OBJECTIVE： To observe the clinical efficacy and safety of ezetimibe combined with simvastatin in the treatment of membranous nephropathy complicated with hyperlipidemia. METHODS： 90 patients with membranous nephropathy complicated with hyperlipidemia were randomly divided into observation group and control group， 45 cases in each group. All patients received health guidance， low-fat diet， and the drugs without interfere with regulating lipid， hepatoprotective and lipid metabolism were forbid. Control group was orally given 20 mg Simvastatin tablet， qd； observation group was additionally given 10 mg Ezetimibe tablet， qd. They were treated for 8 weeks. Clinical efficacy was observed， lipid levels [total cholesterol （TC）， triglyceride （TG）， low density lipoprotein cholesterol （LDL-C）， high density lipoprotein cholesterol （HDL-C）]， aspartate aminotransferase （AST）， alanine aminotransferase （ALT）， urinary protein quatitation， creatine kinase （CK） before and 2， 4， 8 weeks after treatment， and the incidence of adverse reactions were compared. RESULTS： Total effective rates of membranous nephropathy and hyperlipidemia were 95.56％ and 93.30％ in observation group， which were significantly higher than 73.33％ and 75.56％ in control graup， with statistical significance （P＜0.05） .There were no significant differences in TG， HDL-C and LDL-C levels before and 2， 4， 8 weeks after treatment， and TC level before and 2， 4 weeks after treatment between 2 groups （P＞0.05）；after 8 weeks of treatment， TC level in observation group was significantly lower than control group， the differences were statistically significant （P＜0.05）. Compared with control group， there were no significant differences in AST， ALT， urinary protein quatitation and CK level between 2 groups before and 2， 4， 8 weeks after treatment （P＞0.05）. And there was no significant difference in the incidence of adverse reactions between 2 groups （P＞0.05）. CONCLUSIONS： Ezetimibe shows similar clinical efficacy with simvastatin in the treatment of membranous nephropathy complicated with hyperlipidemia， it can effectively reduce TC level， with good safety.